<i>Helicobacter pylori</i>eradication for the prevention of gastric neoplasia

Ford, Alexander C; Forman, David; Hunt, Richard H.; Yuan, Yuhong; Martin, Paul

doi:10.1002/14651858.cd005583.pub2

Cited by 101 publications

(40 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastric cancer is the third most common cause of cancer-related death globally, thus it has been considered as an important public health burden (Hajmanoochehri et al, 2013, Ford et al, 2014, Rahman et al, 2014. Moreover, the prognosis of affected patients is usually poor due to the fact that most cases are diagnosed after age 50 and presented at advanced stage (Lin et al, 2014, Rahman et al, 2014.…”

Section: Discussionmentioning

confidence: 99%

“…The causal relationship between of H. pylori and the development of gastric cancer has been documented in both epidemiological and basic research studies (Parsonnet et al, 1991, Uemura et al, 2001, Demirel et al, 2013, Karami et al, 2013, Basiri et al, 2014 Abebaw et al, 2014). Moreover, a recent meta-analysis has shown that H. pylori eradication potentially reduces the incidence of gastric cancer, especially in the areas where the prevalence of gastric cancer is high (Fock, 2014, Ford et al, 2014.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand

Srinarong¹,

Siramolpiwat²,

Wongcha-um³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Helicobacter pylori (H. pylori) remains an important cause of gastric cancer and peptic ulcer disease worldwide. Treatment of H. pylori infection is one of the effective ways to prevent gastric cancer. However, standard triple therapy for H. pylori eradication is no longer effective in many countries, including Thailand. This study was designed to evaluate the efficacy of adding bismuth and probiotic to standard triple therapy for H. pylori eradication. Materials and Methods: In this prospective single center study, H. pylori infected gastritis patients were randomized to receive 7-or 14-day standard triple therapy plus bismuth with probiotic or placebo. Treatment regimen consisted of 30 mg lansoprazole twice daily, 1 g amoxicillin twice daily, 1 g clarithromycin MR once daily and 1,048mg bismuth subsalicylate twice daily. Probiotic bacteria composed of Bifidobacterium lactis, Lactobacillus acidophilus and Lactobacillus paracasei. Placebo was conventional drinking yogurt without probiotic. CYP2C19 genotyping and antibiotic susceptibility tests were also done. H pylori eradication was defined as a negative 13 C-urea breath test at least 2 weeks after completion of treatment. Results: One hundred subjects were enrolled (25 each to 7-and 14-day regimens with probiotic or placebo). Antibiotic susceptibility tests showed 36.7% metronidazole and 1.1% clarithromycin resistance. CYP2C19 genotyping revealed 40.8%, 49% and 10.2% were rapid, intermediate and poor metabolizers, respectively. The eradication rates of 7-or 14 regimens with probiotics were 100%. Regarding adverse events, the incidence of bitter taste was significantly lower in the 7-day regimen with the probiotic group compared with 7-day regimen with placebo (40% vs. 64%; p=0.04). Conclusions: The 7-day standard triple therapy plus bismuth and probiotic can provide an excellent cure rate of H. pylori (100%) in areas with low clarithromycin resistance such as Thailand, regardless of CYP2C19 genotype. Adding a probiotic also reduced treatment-related adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand

Srinarong¹,

Siramolpiwat²,

Wongcha-um³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Gastric cancer prevention programmes via H.pylori eradication have been shown to benefit high-risk populations [47]. The best results from gastric cancer prevention strategies are obtained when H. pylori eradication is performed before advanced atrophic gastritis with changes becomes established and thus implementation of H. pylori screening and treatment in early adulthood is required.…”

Section: Discussionmentioning

confidence: 99%

Interaction of Helicobacter Pylori with Other Microbiota Species in the Development of Gastric Cancer

Liu¹,

Nie²,

Liang³

et al. 2017

Arch Clin Microbiol

View full text Add to dashboard Cite

Gastric adenocarcinoma is the second-leading cause of cancer-related death in the world. Helicobacter pylori is a Gram-negative bacterial species that selectively colonizes gastric epithelium. The resulting chronic infection is the most significant risk factor for gastric adenocarcinoma identified so far. In the host, H. pylori interacts with microorganisms, which is likely involved in the development of gastric cancer. To identify H. pylori-associated bacteria and explore the contributions of these inter-bacterial events in the process of gastric cancer, we examined the interactions of H. pylori with other microbes in the microbiota community that are implicated in the development and progression of gastric cancer. A better understanding of the complex interactions between H. pylori and altered microbiota is critical to develop personalized therapies and approaches.

show abstract

“…Infection is directly linked to the development of gastritis, gastric ulceration, and gastric cancer [2]. H. pylori is classified as a class I carcinogen in humans and eradication of the organism significantly reduces the risk of developing gastric cancer [3, 4]. Antibiotic resistance is the leading cause for treatment failure, and presents a major challenge in both clinical practice and at a public health level.…”

Section: Introductionmentioning

confidence: 99%

Temporal Trends in Helicobacter pylori Eradication Success in a Test-and-Treat Population

et al. 2018

View full text Add to dashboard Cite

Background/Aims: Although the efficacy of first-line treatment for Helicobacter pylori infection should aim to be > 90%, it is unclear whether this target has been achieved in Israel. We aimed to determine the success rate of treatment for H. pylori and to describe temporal changes in our region. Methods: Adult patients who underwent a first-time C¹³-urea breath test (C¹³-UBT) at Clalit Health Services between January 1, 2010 and December 31, 2015 were included. In order to isolate a naïve “test-and-treat” population who were unlikely to have undergone an initial endoscopy-based H. pylori test, we excluded patients ≥45 years and those with any previous C¹³-UBT. Results: A total of 94,590 subjects (36.1% male, age 28.5 ± 6.0) who underwent at least one C¹³-UBT during the study period were included. C¹³-UBT was positive in 48,509 (51.3%) subjects. A confirmatory post-treatment C¹³-UBT was performed in 37.8, 44.1, 46.6, and 45.9% following 1st, 2nd, 3rd, and 4th-line treatment respectively. Eradication was successful in 65.4% following first-line treatment, and eradication success improved during the study period (59.2, 63.3, 65.7, 66.0, 69.0, and 73.1% in 2010, 2011, 2012, 2013, 2014, and 2015 respectively; OR 1.11; 95% CI 1.09–1.13; p < 0.0001). Eradication was successful in 44.7% following second-line treatment, although eradication success did not significantly improve during the study period (OR 1.05; 95% CI 0.99–1.10; p = 0.09). Conclusions: Despite the increasing success of first-line treatment for H. pylori infection over the study period, eradication rates remain suboptimal. Initiatives to implement the Toronto and Maastricht Consensus Reports should be advanced.

show abstract

Helicobacter pylorieradication for the prevention of gastric neoplasia

Cited by 101 publications

References 71 publications

Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand

Improved Eradication Rate of Standard Triple Therapy by Adding Bismuth and Probiotic Supplement for Helicobacter pylori Treatment in Thailand

Interaction of Helicobacter Pylori with Other Microbiota Species in the Development of Gastric Cancer

Temporal Trends in Helicobacter pylori Eradication Success in a Test-and-Treat Population

Contact Info

Product

Resources

About